Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
6 p.m. Monday on WRAL: Find out why millions of your tax dollars sent to 868 private and religious schools across NC
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Crispr Therapeutics Ag
(NQ:
CRSP
)
47.85
-1.00 (-2.05%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Crispr Therapeutics Ag
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
If You Invested $3,000 in CRISPR Therapeutics in 2018, This Is How Much You Would Have Today
October 16, 2021
The returns haven't been half bad, to say the least.
Via
The Motley Fool
Crispr: A Fallen Angel In Gene Editing
October 16, 2021
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it...
Via
Talk Markets
Market Rally Takes Hold As Leading Stocks Shine; Tesla, Taiwan Semi, Delta In Focus: Weekly Review
October 15, 2021
It's a confirmed rally again, with the major indexes rebounding on strong earnings and falling yields.
Via
Investor's Business Daily
Exposures
Fossil Fuels
BZ Chart Of The Day: Is Crisper Therapeutics About To Rally?
October 15, 2021
Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) may be form...
Via
Benzinga
Analyzing CRISPR Therapeutics's Unusual Options Activity
August 11, 2021
Shares of CRISPR Therapeutics (NASDAQ:CRSP) saw some unus...
Via
Benzinga
The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts
October 14, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Catalyst Biosciences Announces Resignation Of CFO Catalyst Biosciences, Inc...
Via
Benzinga
Exposures
COVID-19
50 Biggest Movers From Yesterday
October 14, 2021
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating...
Via
Benzinga
CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today
October 13, 2021
Crispr Therapeutics (CRSP) stock is falling on Wednesday following the release of new results from a Phase 1 clinical trial.
Via
InvestorPlace
40 Stocks Moving In Wednesday's Mid-Day Session
October 13, 2021
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target...
Via
Benzinga
Why CRISPR Therapeutics Stock Is Sinking Today
October 13, 2021
Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate.
Via
The Motley Fool
Why CRISPR Therapeutics Stock Is Tumbling Today
October 13, 2021
CRISPR Therapeutics AG (NASDAQ: CRSP) is trading lower Wednesday after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refractory CD19+ B-...
Via
Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
October 13, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the...
Via
Benzinga
Exposures
Product Safety
20 Stocks Moving in Wednesday's Pre-Market Session
October 13, 2021
Gainers Puxin Limited (NYSE: NEW) rose 52.1% to $0.6901 in pre-market trading after dipping 24% on Tuesday. Jasper Therapeutics, Inc. (NASDAQ: JSPR) rose 38% to $9.95 in pre-...
Via
Benzinga
Will Crispr Stock — And Its Cancer Drug — Rise After Allogene's Massive Fall?
October 12, 2021
Crispr is planning to begin a registrational test in the first quarter of 2022.
Via
Investor's Business Daily
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
October 10, 2021
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
October 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...
Via
Benzinga
Exposures
COVID-19
Why CRISPR Therapeutics Stock Fell 10.4% Last Month
October 07, 2021
CRISPR Therapeutics stock is now down roughly 33% across 2021's trading.
Via
The Motley Fool
These 3 Top Healthcare Stocks Are Screaming Buys Right Now
September 29, 2021
If the market crashes these companies could be insulated.
Via
The Motley Fool
Biotech Playbook Revisited As Technicals Weaken
September 27, 2021
Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still...
Via
Talk Markets
3 Explosive Biotech Stocks That Could 10X in 10 Years
September 16, 2021
They're leaders in therapeutic areas with massive growth potential.
Via
The Motley Fool
Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market
September 09, 2021
Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day.
Via
Talk Markets
Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought
September 09, 2021
All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.
Via
The Motley Fool
Why Vertex Is Expanding a Gene-Editing Partnership -- and It's not With CRISPR Therapeutics
September 04, 2021
Vertex plans to work more closely on CRISPR gene editing with a small privately-held biotech.
Via
The Motley Fool
Could CRISPR Therapeutics Stock Help You Retire a Millionaire?
August 31, 2021
A crowded field could take years to thin out.
Via
The Motley Fool
Vaccine Victory
August 24, 2021
Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday when the Fed's Jackson...
Via
Talk Markets
Topics
Economy
Exposures
COVID-19
Interest Rates
Product Safety
Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today
August 23, 2021
Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology.
Via
InvestorPlace
Updated Clinical and Financial Data Make the Case for CRISPR Therapeutics
August 19, 2021
Currently trading at a very reasonable multiple, CRSP stock is an undeniable buy.
Via
InvestorPlace
Why CRISPR Therapeutics Stock Fell 25.2% in July
August 06, 2021
The stock dropped roughly $40 per share over the course of the month.
Via
The Motley Fool
Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today
August 05, 2021
Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players.
Via
InvestorPlace
Better Buy: Vertex vs. CRISPR
July 31, 2021
Vertex might be undervalued, CRISPR Therapeutics might be overvalued, but both are looking for a home run.
Via
The Motley Fool
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.